Key points from article :
Chronokines derived from young blood has the potential to stop the cognitive decline in Alzheimer's.
Chronokines are plasma proteins and they increase or decrease with age.
Proprietary formulations of chronokines called plasma fractions are tested against various diseases.
A randomized, double blinded, dose comparison of chronokines were tested against Alzheimer's.
Human subjects on plasma fractions GRF6019 displayed no decline in cognition across a six-month period.
Needs more data to determine how significant this achievement is.
Specific chronokines shown to be effective, need to be identified and synthesized in the future.
Research by Alkahest, a California-based biotech start-up.
